

This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



July 23rd, 2026

Company name: Modalis Therapeutics Corporation

Stock exchange listing: Tokyo Stock Exchange

Ticker/Code number: 4883

URL: <https://www.modalistx.com/en/>

Corporate Representative: Haruhiko Morita

Notice of Japanese Patent Allowance Relating to CRISPR-GNDM® Technology

Modalis Therapeutics Corporation (the “Company”) hereby announces that the Japan Patent Office has issued a patent allowance for the Company’s patent application entitled “Novel Transcriptional Activator” (Japanese Patent Application No. 2021-506361; International Publication No. WO 2020/032057).

The patent relates to a compact transcriptional activator used in the Company’s proprietary CRISPR-GNDM® epigenome-editing technology. The invention resulted from research and development conducted by the Company’s research team led by Dr. Tetsuya Yamagata.

A key technical challenge in achieving tissue-selective epigenome editing using adeno-associated virus (“AAV”) vectors is the limited payload capacity of AAV. Within this limited capacity, it is necessary to accommodate a CRISPR component that recognizes the target DNA sequence, an epigenome-editing module that regulates gene transcription, and a promoter that restricts expression of the delivered genetic components to specific tissues.

The technology covered by this patent is an important foundational technology that reduces the size of the transcriptional activation module used in CRISPR-GNDM®. This increases design flexibility for the individual components and enables all required components to be packaged into a single AAV vector.

This technology supports multiple Company development programs that utilize transcriptional activation. The patent allowance in Japan further strengthens the intellectual property foundation supporting the competitive advantages of CRISPR-GNDM®.

The Company will continue to advance the clinical development of programs utilizing CRISPR-GNDM® while further expanding its global intellectual property portfolio.

For more information, please contact:

Media Contact

Ms. Sawako Nakamura

sawako@modalistx.com